During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles. The management of steroid-refractory chronic ...
The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...
Safety concerns included a 58% rate of treatment-related adverse events, with severe cases like immune-related colitis and a ...
The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...
High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab ...
Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback